公开(公告)号：US20240285573A1

公开(公告)日：2024-08-29

申请号：US18577013

申请日：2022-08-29

申请人： DAEWOONG THERAPEUTICS INC.

发明人： Sang Han PARK ,  Bok Ki KANG ,  Dong Hwan KIM ,  Min Hyeong KANG

IPC分类号： A61K31/351 ,  A61K9/00 ,  A61K31/357 ,  A61K31/381 ,  A61K31/7048 ,  A61K47/10 ,  A61K47/22 ,  A61K47/26 ,  A61K47/44 ,  A61P27/02

CPC分类号： A61K31/351 ,  A61K9/0048 ,  A61K31/357 ,  A61K31/381 ,  A61K31/7048 ,  A61K47/10 ,  A61K47/22 ,  A61K47/26 ,  A61K47/44 ,  A61P27/02

摘要： The present invention relates to a pharmaceutical composition for preventing or treating diabetic eye disease, comprising sodium-glucose cotransporter-2 (SGLT-2) inhibitor, and a method for preventing or treating diabetic eye disease by using same.

公开(公告)号：US20240285519A1

公开(公告)日：2024-08-29

申请号：US18538502

申请日：2023-12-13

申请人： Ocuphire Pharma, Inc.

发明人： Alan Meyer

IPC分类号： A61K9/00 ,  A61K31/417

CPC分类号： A61K9/0048 ,  A61K31/417

摘要： The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.

公开(公告)号：US12070501B1

公开(公告)日：2024-08-27

申请号：US17976660

申请日：2022-10-28

申请人： ADS Therapeutics LLC

发明人： Jinsong Ni ,  Van Dinh ,  Rong Yang

IPC分类号： A01N43/00 ,  A01N43/46 ,  A61K9/00 ,  A61K31/46 ,  A61K31/55 ,  A61K47/06 ,  A61K47/14 ,  A61P27/10

CPC分类号： A61K47/14 ,  A61K9/0048 ,  A61K31/46 ,  A61K47/06 ,  A61P27/10

摘要： A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

公开(公告)号：US12070466B2

公开(公告)日：2024-08-27

申请号：US17335496

申请日：2021-06-01

申请人： Sydnexis, Inc.

发明人： Gregory I. Ostrow ,  Kenneth J. Widder ,  David S. Baker

IPC分类号： A61K31/5575 ,  A61K9/00 ,  A61K9/06 ,  A61K9/08 ,  A61K31/18 ,  A61K31/216 ,  A61K31/565 ,  A61K31/57 ,  A61K47/02 ,  A61K47/34 ,  A61K47/38 ,  A61P27/02

CPC分类号： A61K31/5575 ,  A61K9/0048 ,  A61K9/06 ,  A61K9/08 ,  A61K31/18 ,  A61K31/216 ,  A61K31/565 ,  A61K31/57 ,  A61K47/02 ,  A61K47/34 ,  A61K47/38 ,  A61P27/02

摘要： Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

公开(公告)号：US12064440B2

公开(公告)日：2024-08-20

申请号：US18187507

申请日：2023-03-21

申请人： Somerset Therapeutics, LLC

发明人： Mandar V. Shah ,  Veerappan Subramanian ,  Ilango Subramanian ,  Aman Trehan

IPC分类号： A61K31/5575 ,  A61K9/00 ,  A61K9/06 ,  A61K9/08 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/18

CPC分类号： A61K31/5575 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/06 ,  A61K9/08 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/186

摘要： The present invention provides pharmaceutically acceptable and ophthalmologically suitable gel compositions comprising a therapeutically effective amount of a bimatoprost compound, a therapeutically effective amount of a timolol compound, and benzalkonium chloride. In certain embodiments, compositions provided by the invention further comprise a penetration enhancer component other than benzalkonium chloride. Further, the invention provides a process of preparing such compositions and methods of their use in treating ocular conditions, such as methods of reducing elevated intraocular pressure and/or treating glaucoma, such as open-angle glaucoma.

公开(公告)号：US12064420B2

公开(公告)日：2024-08-20

申请号：US17569838

申请日：2022-01-06

申请人： EyePoint Pharmaceuticals, Inc.

发明人： Kevin Peters

IPC分类号： A61K31/426 ,  A61K9/00 ,  A61P27/02

CPC分类号： A61K31/426 ,  A61P27/02 ,  A61K9/0048

摘要： Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions, for example, intraocular pressure, ocular hypertension, and glaucoma.

公开(公告)号：US20240252648A1

公开(公告)日：2024-08-01

申请号：US18462080

申请日：2023-09-06

申请人： Journey Medical Corporation

发明人： Dov Tamarkin ,  Elana Gazal ,  Yohan Hazot ,  David Schuz ,  Irakliy Papiashvili

IPC分类号： A61K47/44 ,  A61K8/31 ,  A61K8/34 ,  A61K8/36 ,  A61K9/00 ,  A61K9/12 ,  A61K31/137 ,  A61K31/192 ,  A61K31/4164 ,  A61K31/57 ,  A61K31/573 ,  A61K31/593 ,  A61K31/65 ,  A61K45/06 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/24 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/10

CPC分类号： A61K47/44 ,  A61K8/31 ,  A61K8/342 ,  A61K8/361 ,  A61K9/0014 ,  A61K9/0048 ,  A61K9/12 ,  A61K9/122 ,  A61K9/124 ,  A61K31/137 ,  A61K31/192 ,  A61K31/4164 ,  A61K31/57 ,  A61K31/573 ,  A61K31/593 ,  A61K31/65 ,  A61K45/06 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/24 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/10 ,  A61K2800/31 ,  A61K2800/33

摘要： The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.APP

公开(公告)号：US12049495B2

公开(公告)日：2024-07-30

申请号：US16871765

申请日：2020-05-11

申请人： Novartis AG

发明人： Huixiang Zhang ,  Charles Boring ,  Alok Kulshreshtha ,  Yuhong Zeng ,  Li Wan ,  Laman Alani

IPC分类号： A61K39/395 ,  A61B3/12 ,  A61B5/00 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  C07K16/22 ,  A61K39/00

CPC分类号： C07K16/22 ,  A61B3/12 ,  A61B5/4848 ,  A61K9/0048 ,  A61K39/3955 ,  A61K39/39591 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/94

摘要： The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.

公开(公告)号：US12048746B2

公开(公告)日：2024-07-30

申请号：US17462654

申请日：2021-08-31

申请人： SESEN BIO, Inc.

发明人： Grigorios Zarbis-Papastoitsis ,  Patricia Lowden

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  C07K16/24

CPC分类号： A61K39/39591 ,  A61K9/0019 ,  A61K9/0048 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  C07K16/248 ,  C07K2317/94

摘要： Featured herein are pharmaceutical compositions and formulations containing an interleukin-6 (IL-6) antagonist, e.g., an IL-6 antibody molecule, designed for administration for a subject. The pharmaceutical compositions and formulations provided herein are suitable for use in manufacture of medicaments or methods of treating subjects with IL-6 associated diseases, e.g., ocular diseases associated with elevated levels of IL-6.

公开(公告)号：US12048702B2

公开(公告)日：2024-07-30

申请号：US17271468

申请日：2019-08-29

申请人： APROFOL AG

发明人： Martin Ulmann ,  Gerd Wiesler ,  Josef Flammer

IPC分类号： A61K31/525 ,  A61K9/00 ,  A61K9/08 ,  A61K33/04 ,  A61P27/06

CPC分类号： A61K31/525 ,  A61K9/0048 ,  A61K9/08 ,  A61K33/04 ,  A61P27/06

摘要： Preparations of folate for use in the treatment of eye disorders in the presence of elevated intraocular pressure. Methods of reducing intraocular pressure in a patient having an eye disease.